Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Amarin Corporation PLC AMRN

Healthcare  —  Drug Manufacturers General
13.20 (0.23) (1.71%) as of 25 Sep
Market cap
$283.6M
P/E
0.0×
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Amarin Corporation PLC (AMRN) Business Profile

Updated before January 2025

Company Overview

Amarin Corporation PLC (NASDAQ: AMRN) is a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health. Founded in 1993, the company is headquartered in Dublin, Ireland, with additional operations in Bridgewater, New Jersey, USA. Amarin’s leadership team includes experienced professionals in the pharmaceutical and biotechnology industries, with Karim Mikhail serving as the President and Chief Executive Officer. The company has a strong commitment to innovation and aims to address unmet medical needs in cardiovascular health.

Core Business Segments

Amarin’s core business revolves around the development and commercialization of prescription-grade omega-3 fatty acid products. The company’s flagship product is VASCEPA® (icosapent ethyl), which has been approved for use in multiple countries to reduce cardiovascular risk in patients with elevated triglycerides and other risk factors.

Key Products and Services

  • VASCEPA® (icosapent ethyl):

    • Approved by the U.S. Food and Drug Administration (FDA) in 2012 for the treatment of severe hypertriglyceridemia.
    • In 2019, the FDA expanded its approval to include cardiovascular risk reduction in patients with elevated triglycerides and established cardiovascular disease or diabetes with additional risk factors.
    • VASCEPA has also received approval in the European Union, Canada, and other regions, making it a globally recognized product.

  • Pipeline Development:

    • Amarin is actively exploring additional therapeutic applications for VASCEPA and other omega-3-based products.
    • The company invests in clinical trials to expand the scientific understanding of its products and their potential benefits.

Business Model

Amarin’s business model is centered on the development, regulatory approval, and commercialization of innovative therapies for cardiovascular health. The company generates revenue primarily through the sale of VASCEPA. Its approach includes:

  • Research and Development (R&D):

    • Significant investment in clinical trials to validate the efficacy and safety of its products.
    • Collaboration with academic institutions and research organizations to advance scientific knowledge.

  • Global Commercialization:

    • Establishing partnerships with pharmaceutical companies to distribute VASCEPA in international markets.
    • Direct sales efforts in the United States and other key regions.

  • Patient and Physician Education:

    • Raising awareness about the importance of cardiovascular health and the role of omega-3 fatty acids in reducing risk factors.

Strategic Direction

Amarin is focused on expanding its global footprint and diversifying its product portfolio. Key strategic priorities include:

  • Geographic Expansion:

    • Increasing market penetration in Europe, Asia, and other regions where VASCEPA has been approved.
    • Seeking regulatory approval in additional countries to broaden its reach.

  • Pipeline Growth:

    • Exploring new therapeutic indications for VASCEPA, such as its potential role in treating other chronic diseases.
    • Investing in R&D to develop next-generation omega-3-based therapies.

  • Sustainability Goals:

    • Committing to environmentally sustainable practices in the sourcing and production of omega-3 fatty acids.
    • Reducing the environmental impact of its operations and supply chain.

Competitive Landscape

Amarin operates in a highly competitive biopharmaceutical market. Key competitors include:

  • Pharmaceutical Companies:

    • Companies like AstraZeneca and Pfizer, which offer alternative therapies for cardiovascular health.

  • Nutritional Supplement Providers:

    • Manufacturers of over-the-counter omega-3 supplements, which may be perceived as alternatives to prescription-grade products like VASCEPA.

  • Generic Drug Manufacturers:

    • Companies producing generic versions of omega-3-based therapies, which could impact Amarin’s market share.

Risk Factors

Amarin faces several risks that could impact its business operations and financial performance:

  • Market Dependence:

    • Reliance on VASCEPA as the primary revenue driver makes the company vulnerable to changes in market demand or regulatory challenges.

  • Regulatory Risks:

    • The biopharmaceutical industry is heavily regulated, and any delays or issues with regulatory approvals could affect Amarin’s growth.

  • Supply Chain Disruptions:

    • Dependence on third-party suppliers for raw materials and manufacturing could lead to disruptions in product availability.

  • Competition:

    • The entry of generic competitors and alternative therapies could erode market share and pricing power.

Recent Developments

Amarin has made significant strides in recent years, including:

  • Global Approvals for VASCEPA:

    • Securing regulatory approval in the European Union, Canada, and other regions.
    • Launching VASCEPA in new markets to expand its global presence.

  • Clinical Trial Results:

    • Publishing data from the REDUCE-IT trial, which demonstrated the cardiovascular benefits of VASCEPA in high-risk patients.

  • Corporate Strategies:

    • Strengthening partnerships with international distributors to accelerate market entry.
    • Implementing cost-saving measures to improve operational efficiency.

Investment Considerations

Strengths:

  • Proven Product:

    • VASCEPA is a well-established, FDA-approved therapy with demonstrated efficacy in reducing cardiovascular risk.

  • Global Expansion:

    • Ongoing efforts to enter new markets provide growth opportunities.

  • Strong Clinical Data:

    • Robust clinical trial results support the safety and efficacy of VASCEPA.

Risks:

  • Market Concentration:

    • Heavy reliance on a single product for revenue generation.

  • Regulatory and Competitive Challenges:

    • Potential for increased competition from generic drugs and alternative therapies.

  • Supply Chain Vulnerabilities:

    • Dependence on third-party suppliers for raw materials and manufacturing.

Conclusion

Amarin Corporation PLC is a leading player in the biopharmaceutical industry, with a strong focus on cardiovascular health. The company’s flagship product, VASCEPA, has gained global recognition for its ability to reduce cardiovascular risk in high-risk patients. While Amarin faces challenges such as market dependence and competition, its strategic initiatives, including geographic expansion and pipeline growth, position it for long-term success. Investors should weigh the company’s strengths and risks when considering it as a potential investment opportunity.